CTuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:arcinomatous meningitis in a patient with Her2/neu expressing bladder cancer following trastuzumab and chemotherapy: a case report and review of the literature | JOURNAL OF MEDICAL Sr CASE REPORTS Open Access Case report Carcinomatous meningitis in a patient with Her2 neu expressing bladder cancer following trastuzumab and chemotherapy a case report and review of the literature Oscar B Goodman Jr1 Matthew I Milowsky2 Jodi Kaplan2 Maha Hussain3 and David M Nanus2 Addresses 1Division of Clinical Oncology Nevada Cancer Institute Las Vegas NV 89135 USA 2Division of Hematology and Medical Oncology Department of Medicine Weill Medical College of Cornell University - New York Presbyterian Hospital New York nY 10021 USA 3Division of Hematology and Medical Oncology Department of Medicine University of Michigan Ann Arbor MI 48109 USA Email DMN - dnanus@ Corresponding author Received 18 August 2008 Accepted 8 April 2009 Published 15 September 2009 Journal of Medical Case Reports 2009 3 9110 doi 1752-1947-3-9110 This article is available from http jmedicalcasereports article view 9110 2009 Goodman Jr et al. licensee Cases Network Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Targeted therapies may impact the natural history of bladder cancer based upon their pharmacokinetics. The Her2 neu receptor tyrosine kinase overexpressed by half of all primary urothelial carcinomas has recently been examined as a therapeutic target in bladder cancer in a prospective phase II multicenter trial NCI-198 that enrolled 109 patients with advanced bladder carcinomas for treatment with trastuzumab in combination with paclitaxel carboplatin and gemcitabine. We report on documented isolated Her2 neu positive carcinomatous meningitis in a patient treated with trastuzumab. Case presentation A 61-year-old Caucasian man with metastatic bladder cancer was treated with .
